Tiagabine monotherapy in the treatment of partial epilepsy

Epilepsia
S C Schachter

Abstract

Three studies were conducted to assess tiagabine (TGB) hydrochloride monotherapy in patients with partial seizures. The first was a double-blind, placebo-controlled trial of 11 patients (seven TGB, four placebo) undergoing evaluation for epilepsy surgery. Baseline antiepileptic drug (AED) therapy was discontinued abruptly before monotherapy. Although 24-h seizure rates increased during monotherapy in both groups, patients receiving TGB experienced fewer seizures than placebo patients. Subsequent studies (an open-label, dose-ranging study; n=31 and a double-blind, randomized comparison of 6 and 36 mg/day TGB; n=102 and 96, respectively) involved discontinuation of baseline AEDs. In the dose-ranging study, 19 of 31 patients (61%) converted to TGB monotherapy, with a mean final dose of 38.4 mg/day (range 24-54 mg/day) in those who completed the study (n=12). In the low-vs. high-dosage study, median 4-week complex partial seizure rates decreased significantly in patients from both dose groups who completed the monotherapy period (p<0.05 compared with baseline). In the intent-to-treat analysis, significantly more patients in the high-dose group experienced a reduction in seizures of at least 50% compared with the low-dose group (p =...Continue Reading

Citations

Mar 20, 2002·Current Neurology and Neuroscience Reports·C W Bazil
Mar 27, 2004·Current Treatment Options in Neurology·John R. Gates
Nov 30, 2000·Current Treatment Options in Neurology·M D Privitera, J P Szaflarski
Jan 24, 2004·Pediatric Neurology·Roberto H CaraballoNatalio Fejerman
Mar 26, 2003·Seizure : the Journal of the British Epilepsy Association·Taoufik M Alsaadi, Catherine Thieman
Nov 5, 1997·Seminars in Pediatric Neurology·G L Holmes
Aug 25, 2001·Epilepsia·P GentonE Perucca
Jun 26, 2003·Epilepsia·Antonio Gil-Nagel
Apr 1, 1997·Epilepsia·D BuckD W Chadwick
Mar 24, 1998·Annual Review of Medicine·C W Bazil, T A Pedley
Nov 24, 1998·Journal of Clinical Pharmacology·M S ThomsenT Kruse
Aug 11, 2000·Pharmacotherapy·J M Pellock
Nov 23, 2001·Pharmacotherapy·T A Glauser
Feb 5, 1998·Lancet·J P Leach, M J Brodie
Mar 27, 2004·Current Treatment Options in Neurology·Susan T. Herman
Oct 26, 1999·Epilepsia·S C Schachter
May 13, 1998·Epilepsia·C B DodrillK W Sommerville
Nov 20, 2015·Lancet Neurology·Scott MintzerMichel Baulac
Mar 13, 2003·Mayo Clinic Proceedings·Randa G Jarrar, Jeffrey R Buchhalter
Jul 17, 2007·Drug and Alcohol Dependence·Theresa WinhusenAhmed Elkashef
Jul 10, 2007·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Frank J E Vajda
Jun 26, 2007·Epilepsy & Behavior : E&B·Erik K St LouisThomas Bramley
Dec 29, 2004·The Lancet Infectious Diseases·Adrian EleyFrancesco Galdiero
Mar 1, 1997·Seminars in Pediatric Neurology·J M Pellock, N Watemberg
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P H McCabe
May 5, 2001·Expert Opinion on Pharmacotherapy·S C Schachter
Oct 20, 1998·Journal of the American Geriatrics Society·J I Sirven
Sep 14, 2000·Seizure : the Journal of the British Epilepsy Association·T FakhouryB Abou-Khalil
Jan 15, 2005·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·B L Y CheukS W K Cheng
Oct 30, 2013·ISRN Pharmacology·Priscilla Kolibea ManteElvis Ofori Ameyaw
Dec 7, 2000·Mental Retardation and Developmental Disabilities Research Reviews·J M Pellock, L D Morton
Sep 1, 2000·Acta Neuropsychiatrica·H C GrunzeJ Waiden
Oct 26, 1999·Epilepsia·J M Pellock, R Appleton

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.